BOSTON, Sept. 21 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company is receiving multiple new purchase orders for its MammoView(TM) line of surgical endoscopy instruments from approximately 30 hospitals, which Solos has added to their client base over the last 12 months. More than half of the purchase orders are coming from teaching hospitals affiliated with prestigious public and private Universities across the Country.
In addition to providing the world's most advanced medical care, teaching hospitals educate and train the next generation of physicians. Every year, approximately 16,000 graduates of the nation's 130 medical schools begin their residency training at U.S. teaching hospitals. Physicians at these institutions have pioneered new, advanced medical procedures that are now staples of clinical care.
"The MammoView(TM) product line is revolutionary in that it employs advanced micro endoscopes and optical technology, which can detect precancerous and cancerous cells approximately five years before a mammogram would. For this reason, we expect to continue to receive an increase in new purchase orders, as well as re-orders, from highly-regarded University teaching hospitals," stated Bob Segersten, President of Solos Endoscopy, Inc.
Solos Endoscopy, Inc. recently announced that the Company has received multiple purchase orders for its MammoView(TM) line of surgical endoscopy instruments from the National Cancer Institute (NCI). NCI is 1 of 27 Institutes and Centers that comprise the U.S. National Institutes of Health, which is part of the U.S. Department of Health and Human Services.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2009 PR Newswire.
All rights reserved